The decision was made in a board meeting held on Friday, and the development was announced during market hours. Following the news, the company’s shares jumped 2% to hit the day’s high of Rs 887 on the NSE.
The buyback will be carried out through the tender offer route, in accordance with Securities and Exchange Board of India (Sebi) regulations, the company said in a filing to the exchanges.
The total buyback size constitutes 9.8% of the company’s paid-up equity capital and free reserves, based on its latest audited financials as of March 31, 2025. The offer will be open to all eligible public shareholders, while promoters and promoter group entities have expressed their intention not to participate.
As per regulatory norms, 15% of the buyback size will be reserved for small shareholders, ensuring wider retail participation.
The company has fixed April 24, 2026, as the record date to determine shareholder eligibility. It has also constituted a buyback committee to oversee the process and appointed Fintellectual Corporate Advisors as the merchant banker for the transaction.
The board retains the flexibility to revise the buyback price upward while proportionately reducing the number of shares, without altering the overall buyback size.Shares of Windlas Biotech have rallied over 20% over a one-year period. However, they are market underperformers, sliding over 18% in the past 12 months. Nifty’s one-year returns in the same period are to the tune of 4%, while those of the BSE Sensex are at 2%.
Also read: Akshaya Tritiya 2026: Gold stocks soar up to 25% in a month! Will rally soften after auspicious festival?
Thanks to the late rally, the stock is currently trading above its 50-day and 200-day simple moving averages (SMAs) of Rs 780 and Rs 863, respectively, according to Trendlyne data.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)